Abstract
High-risk prostate cancer requests external beam irradiation combined with androgen deprivation therapy (ADT) to potentiate irradiation, whatever its technique, and to destroy the infra-clinical disease located outside the planning treatment volume. Randomized phase III trials have paved the way for establishing the indications and the duration of androgen deprivation therapy. Image-guided intensity modulated radiotherapy is the gold standard. Long term androgen deprivation therapy (≥2 years) with luteinizing hormone-releasing hormone agonists combined with external irradiation should be recommended for high-risk prostate cancer. For intermediate-risk localized prostate cancer, patients may benefit from a combined approach with a short term ADT (4–6 month); for patients unsuitable for ADT, due to co-morbidities or unwilling to accept androgen deprivation therapy to preserve their sexual health, the recommended treatment is intensity modulated radiotherapy at a dose of 76–80 Gy or a combination of intensity modulated radiotherapy and brachytherapy. The patients need to be informed of the potential morbidity of ADT and a close cooperation is needed with general practitioners and specialists to prevent and mitigate side effects and maintain quality of life.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Asbell SO, Krall JM, Pilepich MV, et al. Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77–06. Int J Radiat Oncol Biol Phys. 1988;15:1307–16.
Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33.
Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserilin. N Engl J Med. 1997;337:295–300.
Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360:103–6.
Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009;360:2516–27.
Bolla M, Hannoun-Levi JM, Ferrero JM, et al. Concurrent and adjuvant docetaxel with three-dimensional conformal radiation therapy plus androgen deprivation for high-risk prostate cancer: preliminary results of a multicentre phase II trial. Radiother Oncol. 2010;97:312–7.
Bolla M, van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomized study. Lancet Oncol. 2010;11:1066–73.
Bolla M, Maingon P, Carrie C, et al. Short term androgen suppression and radiation dose escalation for intermediate and high-rsk localized prostate cancer: results of EORTC trial 22991. J Clin Oncol. 2016;34(15):1748–56. http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.64.8055.
Briganti A, Karnes RJ, Da Pozzo LP, et al. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. Eur Urol. 2011;59:832–40.
D’Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25:2420–5.
D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299:289–95.
D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Long-term follow-up of a randomized trial of radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA. 2015;314:1291–3.
De Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastattic prostate cancer. N Engl J Med. 2011;364:1995–2005.
Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005;6:841–50.
Denham JW, Steigler A, Lamb DS, et al. Short term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011;12(5):451–9.
Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer. 2004;100:892–9.
Dubray BM, Beckendorf V, Guerif S, et al. Does short-term androgen depletion add to high-dose radiotherapy (80 Gy) in localized intermediate-risk prostate cancer? Intermediate analysis of GETUG 14 randomized trial (EU-20503/NCT00104741). J Clin Oncol. 2011;29:(suppl; abstr 4521).
Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92–02. Eur Urol. 2008;54:816–23.
Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85–31. J Clin Oncol. 2009;27:92–9.
Fizazi K, Lesaunier F, Delva R, et al. Docetaxel-estramustine in high-risk localized prostate cancer: first results of the French Genitourinary Tumor Group phase III trial (GETUG12). J Clin Oncol. 2011;29:(suppl; abstr 4513).
Fizazi K, Lesaunier F, Delva R, et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomzed trial. Lancet Oncol. 2015;16:787–94.
Fossa SD, et al. Ten-and 15-year prostate cancer-specific mortality in patients with non metastatic locally advanced or aggressive intermediate prostate cancer, randomized to lifelong endocrine treatment alone or combined with radiotherapy; final results of the Scandinavian Prostate Cancer Group-7. Eur Urol. 2016;70(4):684–91. http://dx.doi.org/10.1016/j.euro.2016.03.021.
Goodwin JF, Schiewer MJ, Dean JL, et al. A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov. 2013;3:1254–71.
Granfors T, Modig H, Damber JE, Tomic R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol. 1998;159:2030–4.
Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and localized treatment with curative intent. Update 2013. Eur Urol. 2014;65:124–37.
Hennequin C, Giocanti N, Favaudon V. S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. Br J Cancer. 1995;71:1194–8.
Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92–02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008;26:2497–504.
Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43:209–43.
ICECap Working Group. The development of intermediate clinical endpoints in cancer of the prostate (ICECaP). J Natl Cancer Inst. 2015;107:1–8.
James ND, Spears MR, Clarke NW, et al. Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer. JAMA Oncol. 2015;2(3):348–57. doi:10.1001/jamaoncol.2015.4350 1–10.
Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011;365:107–18.
Joon DL, Hasegawa M, Sikes C, et al. Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys. 1997;38:1071–7.
Kalbasi A. Dose escalated irradiation and overall survival in men with non metastatic prostate cancer. JAMA Oncol. 2015;1:897–906.
Kaminski JM, Hanlon AL, Joon DL, Meistrich M, Hachem P, Pollack A. Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth. Int J Radiat Oncol Biol Phys. 2003;57:24–8.
Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prosytate cancer. BJU Int. 2008;102:1531–8.
Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res. 2009;15:4792–8.
Kumar P, Perrotti M, Weiss R, et al. Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate. J Clin Oncol. 2004;22:1909–15.
Lawton CA, Winter K, Byhardt R, et al. Androgen suppression plus radiation versus radiation alone for patients with D1/pathologic node-positive adenocarcinoma of the prostate : updated results based on a national prospective randomized trial, Radiation Therapy Oncology Group 85–31. Int J Radiat Oncol Biol Phys. 2005;23:800–7.
Lawton CA, DeSivio M, Roach 3rd M, et al. An update of the phase III trial comparing whole pelvis to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression.: update analysis of RTOG 94–13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys. 2007;69:646–55.
Lawton CA, Winter K, Murray K, et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85–31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;49:937–9.
Labrie F, Belanger A, Simard J, Labrie C, Dupont A. Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy. Cancer. 1993;71:1059–67.
Lalonde E, Ishkanian AS, Sykes J, et al. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncol. 2014;15:1521–32.
Lin CC, Gray PJ, Jemal A, Efstathiou JA. Androgen deprivation with or withoiut radiation therapy for clinically node-positive prostate cancer. J Natl Cancer Inst. 2015;107:1–10.
Mason M. Final report of the Intergroup Randomized Study of Ciombined Androgen deprivationtherapy plus radiotherapy versus androgen deprivation therapy alone in locally advanced prostate cancer. J Clin Oncol. 2015;33:2143–9.
Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet. 2000;355:1491–8.
Milosevic M, Chung P, Parker C, et al. Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radition response. Cancer Res. 2007;67:6022–5.
Mottet N, Peneau M, Mazeron J-J, Molinie V, Richaud P. Addition of radiotherapy to long term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. Eur Urol. 2012;62:213–9.
Mottet N, Bellmunt J, Briers E, et al. members of the EAU – ESTRO – SIOG Prostate Cancer Guidelines Panel. EAU – ESTRO – SIOG guidelines on prostate cancer. Edn. Presented at the EAU Annual Congress Munich 2016. EAU Guidelines Office, Arnhem; 2016. ISBN 978-90-79754-98-4. https://uroweb.org/guideline/prostate-cancer/.
Nabid A, Carrier N, Martin AG, et al. High-risk prostate cancer treated with pelvic radiotherapy and 36 months versus 18 months of androgen blockade. Results of a phase III randomized study. J Clin Oncol. 2013;31:(suppl 6; abstr 3).
Nguyen PL, Alibhai SMH, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67:825–36.
Parmar H, Philipps RH, Lightman SL, Edwards L, Allen L, Schally AV. Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma. Lancet. 1985;2:1201–5.
Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.
Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of phase III RTOG 85–31. Int J Radiat Oncol Biol Phys. 2005;61:1285–90.
Pisansky TM, Hunt D, Gomella LG, et al. Duration of androgen suppression before radiotherapy for localized prostate cancer: Radiation Therapy Oncology Group randomized clinical trial 9910. J Clin Oncol. 2015;33:332–9.
Pommier P, Chabaud S, Lagrange JL, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol. 2007;25:5366–73.
Potosky AL, Knopf K, Clegg LX, et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol. 2001;19:3750–7.
Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–48.
Roach 3rd M, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 86–10. J Clin Oncol. 2008;26:585–91.
Sandler HM, et al. J Clin Oncol. 2015;33:(15S).
Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in proste cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.
Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature. 1979;277:665–7.
Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2007;352:154–64.
Smith MR, Bae K, Efstathiou JA, et al. Diabetes and mortality in men with locally advanced prostate cancer. J Clin Oncol. 2008;26:4333–9.
Smith MR, Lee H, McGovern F, et al. Metabolic changes during gonadotrophin-releasing hormone agonist therapy for prostate cancer. Differences from the classic metabolic syndrome. Cancer. 2008;112:2188–94.
Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745–55.
Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.
Tran E, Paquette M, PicklesT et al. Population-based validation of a policy change to use long-term androgen deprivation therapy for cT3-4 prostate cancer: impact of the EORTC22863 and RTOG 85-31 and 92-02 trials. Radioth Oncol, 2013;107(3):366–71.
Tyrell CJ, Payne H, See WA, et al. Bicalutamide (‘Casodex’) 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer:results from the randomised early prostate cancer programme. Radiat Oncol. 2005;76:4–10.
Valicenti RK, Kwounghwa B, Michalski J, et al. Does hormone therapy reduce disease recurrence in prostate cancer patienst receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94–06. Int J Radiat Oncol Biol Phys. 2011;79:1323–2912.
Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys. 2009;74(5):1405–18.
Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373:301–30.
Zietman AL, Prince EA, Nakfoor BM, Park JJ. Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys. 1997;38:1067–70.
Zapatero A, Valcarcel F, Calvo FA, et al. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. J Clin Oncol. 2005;23:6561–8.
Zapatero A, Guerrero A, Maldonado X, et al. High-dose radiotherapy with short-term or long term androgen deprivation in localized prostate cancer (DART01/05 GICOR): a randomized, controlled, phase 3 trial. Lancet Oncol. 2015;16:320–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Bolla, M., Verry, C., Iriart, C. (2017). Combination of Androgen Deprivation Therapy and Radiation Therapy for Locally Advanced and Localized Prostate Cancer. In: Bolla, M., van Poppel, H. (eds) Management of Prostate Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-42769-0_15
Download citation
DOI: https://doi.org/10.1007/978-3-319-42769-0_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-42768-3
Online ISBN: 978-3-319-42769-0
eBook Packages: MedicineMedicine (R0)